In vivo applications of PEG liposomes: unexpected observations
- PMID: 11789675
In vivo applications of PEG liposomes: unexpected observations
Abstract
Recent studies with PEG liposomes in patients have consistently shown that liposomes can induce side effects (flushing, tightness of the chest). Furthermore, the blood clearance of PEG liposomes was shown to be dose-dependent: at lipid doses lower than 1 micromol/kg, PEG liposomes do not show the long-circulation property but instead are cleared relatively rapidly from the bloodstream. Another remarkable observation was that repeated injections of PEG liposomes led to significant pharmacokinetic changes: the circulatory half-life of a second dose of radiolabeled PEG liposomes dramatically decreased when given from 5 days to up to 4 weeks after a first injection. In these three unexpected phenomena, proteins of the complement system seem to play a key role. Therefore, one has to consider that PEG liposomes are not inert drug-carrying vehicles in vivo. Pharmacological effects can occur, induced solely by using liposomal particles irrespective of the drug content.
Similar articles
-
Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection.J Pharmacol Exp Ther. 2001 Aug;298(2):607-12. J Pharmacol Exp Ther. 2001. PMID: 11454922
-
Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.J Pharm Pharmacol. 2012 Mar;64(3):372-82. doi: 10.1111/j.2042-7158.2011.01422.x. Epub 2011 Dec 16. J Pharm Pharmacol. 2012. PMID: 22309269
-
Preclinical and clinical evidence for disappearance of long-circulating characteristics of polyethylene glycol liposomes at low lipid dose.J Pharmacol Exp Ther. 2000 Jun;293(3):996-1001. J Pharmacol Exp Ther. 2000. PMID: 10869403
-
Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes.Int J Pharm. 2008 Apr 16;354(1-2):56-62. doi: 10.1016/j.ijpharm.2007.11.005. Epub 2007 Nov 9. Int J Pharm. 2008. PMID: 18083313 Review.
-
Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates.Adv Drug Deliv Rev. 2004 Apr 29;56(8):1177-92. doi: 10.1016/j.addr.2004.01.011. Adv Drug Deliv Rev. 2004. PMID: 15094214 Review.
Cited by
-
Stealth properties to improve therapeutic efficacy of drug nanocarriers.J Drug Deliv. 2013;2013:374252. doi: 10.1155/2013/374252. Epub 2013 Mar 7. J Drug Deliv. 2013. PMID: 23533769 Free PMC article.
-
Nanovehicular intracellular delivery systems.J Pharm Sci. 2008 Sep;97(9):3518-90. doi: 10.1002/jps.21270. J Pharm Sci. 2008. PMID: 18200527 Free PMC article. Review.
-
Polymer therapeutics in surgery: the next frontier.J Interdiscip Nanomed. 2016 Apr;1(1):19-29. doi: 10.1002/jin2.6. Epub 2016 Apr 18. J Interdiscip Nanomed. 2016. PMID: 27588210 Free PMC article. Review.
-
The effects of nanoparticle drug loading on the pharmacokinetics of anticancer agents.Nanomedicine (Lond). 2015 Feb;10(3):447-63. doi: 10.2217/nnm.14.179. Nanomedicine (Lond). 2015. PMID: 25707978 Free PMC article. Review.
-
Liposome-encapsulated EF24-HPβCD inclusion complex: a preformulation study and biodistribution in a rat model.J Nanopart Res. 2011 Jun 1;13(6):2609-2623. doi: 10.1007/s11051-010-0154-5. J Nanopart Res. 2011. PMID: 21779150 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources